XML 34 R23.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information
 3 Months Ended
Mar. 31, 2017
Segment Reporting [Abstract]  
Segment Information
Segment Information

In connection with the contemplated sale of the remaining interest in PCT to Hitachi Chemical, we reorganized our financial reporting into two distinct reportable operating segments.
•
The R&D Segment which develops early-stage cellular therapeutic candidates to treat certain diseases with the intention of partnering these candidates post proof-of-concept in humans.
•
The PCT Segment which provides development and manufacturing services to the cell and cell-based gene therapy industry.
Each operating segment is individually reviewed and evaluated by our Chief Operating Decision Maker (CODM), who allocates resources and assesses performance of each segment individually. The CODM evaluates segment performance primarily based on loss from operations. The Company's Chief Executive Officer has been identified as the CODM.
The following table shows, by segment: net revenue, cost of sales, operating profit, depreciation and amortization, interest expense, income tax benefit (expense), and assets for the three months ended March 31, 2017 and 2016 ($ in thousands):
 
 
Three Months Ended March 31, 2017
 
Three Months Ended March 31, 2016
 
 
R&D Segment
 
PCT Segment
 
Total
 
R&D Segment
 
PCT Segment
 
Total
Net revenues
 
$
—

 
$
7,922.7

 
$
7,922.7

 
$
—

 
$
7,489.5

 
$
7,489.5

Cost of revenues
 
—

 
8,042.3

 
8,042.3

 
—

 
6,228.3

 
6,228.3

Operating loss
 
(7,736.6
)
 
(1,795.1
)
 
(9,531.7
)
 
(10,876.3
)
 
(197.0
)
 
(11,073.3
)
Depreciation and amortization
 
98.9

 
556.4

 
655.3

 
153.1

 
584.1

 
737.2

Interest expense
 
158.9

 
8.8

 
167.7

 
897.2

 
29.6

 
926.8

Provision for income taxes
 
—

 
49.5

 
49.5

 
—

 
53.4

 
53.4

 
 
 
 
 
 
 
 
 
 
 
 
 
Total assets
 
$
13,049.0

 
$
35,479.5

 
$
48,528.4

 
$
21,883.7

 
$
41,301.2

 
$
63,184.9